pancreatic cancer

HUTCHMED has advanced its pancreatic cancer program to Phase III, initiating a trial for a combination therapy of surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine (S+C+AG) for metastatic PDAC in China. Promising Phase II results showed significant improvements in progression-free survival and objective response rate compared to the standard chemotherapy regimen. The Phase III trial will evaluate overall survival as the primary endpoint in approximately 400 additional patients.

Actuate Therapeutics announced positive Phase 2 results for elraglusib in previously untreated metastatic pancreatic cancer. The combination with gemcitabine/nab-paclitaxel significantly improved overall survival to 10.1 months, compared to 7.2 months for the control, with a 37% reduction in death risk. The 12-month survival rate also doubled. Actuate plans to discuss product registration with the FDA.

A Phase 3 trial (PANOVA-3) showed that Tumor Treating Fields (TTFields) therapy combined with gemcitabine and nab-paclitaxel improved overall survival in patients with unresectable, locally advanced pancreatic cancer and reduced pain duration compared to chemotherapy alone. The results are published in the *Journal of Clinical Oncology* and will be presented at ASCO. Novocure plans to submit the data to the FDA for approval.